NeuroSearch discovers new treatment principle for incontinence  

NeuroSearch has announced a new incontinence treatment mechanism, derived from its ion channel research

NeuroSearch has discovered a new mechanism for treating incontinence, a condition that afflicts millions of people around the world. The discovery was presented yesterday at the Biophysical Society conference held in San Antonio, Texas. The principle is derived from NeuroSearch's ion channel research, and the company has already identified drugs that demonstrate promising efficacy in animal models of incontinence. At the conference, preclinical data produced in collaboration with Professor Karl-Erik Andersson of Lund University, Sweden for the prototype drug NS309 was presented. Professor Andersson is one of the leading scientists in the field of incontinence.


NeuroSearch is a Danish biopharmaceutical company with compounds in clinical development and a portfolio of drug discovery programmes primarily focused on ion channel modulators with attractive therapeutic and commercial potential in CNS and other diseases. The company has strategic alliances with Abbott Laboratories, Boehringer Ingelheim, GlaxoSmithKline, National Institute on Drug Abuse (NIDA), Organon, Pharmexa and Pierre Fabre.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×